Meta Pixel

News and Announcements

How To Write An Email To An Investor

  • Published December 14, 2022 5:01AM UTC
  • Publisher Osama Hassan
  • Categories Capital Raising Tips

The Dos and Don’ts of writing your first email to an investor:

Dos: 

1. Make it short (less than 60 seconds to read)

2. Describe the problem you’re solving

3. Describe your solution

4. Have you launched?

5. Have you got a technical co-founder, industry expertise?

6. Describe what makes your solution different (do you have an IP or patent?)

7. Use a company e-mail address

8. Use simple language (your users know the jargon of your industry, assume investors don’t)

9. Track open rates to see who is actually reading your emails

Don’ts:

1. Don’t make your first email long

2. Don’t construct a long story (at the beginning investors are not interested in how you came up with the idea, state raw facts)

3. Don’t send multiple follow-up emails quickly (you want to begin a back-and-forth conversation so give

4. Don’t attach a pitch-deck that doesn’t follow a template that investors are not used to (remember, you don’t have to attach a pitch-deck)

✌️

Click here to view the original Linkedin post.

Looking for a platform to raise capital? Click here to discover how Wholesale Investor can help you.

Your capital engagement platform

With a 14-year track record, a network of 32,000+ investors, and a capital raising platform, Wholesale investor is a leading investment platform for start-ups, scale-ups, emerging growth companies, and small caps.

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now